	US 11,680,050 B2
	Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Minhua Chen, Suzhou (CN); Xiaoyu Zhang, Suzhou (CN); Yanfeng Zhang, Suzhou (CN); Chaohui Yang, Suzhou (CN); Xiaoting Zhai, Suzhou (CN); and Kaiqiang Yan, Suzhou (CN)
Assigned to RECEPTOS LLC, New York, NY (US)
Filed by RECEPTOS LLC, New York, NY (US)
Filed on Jan. 21, 2020, as Appl. No. 16/748,303.
Application 16/748,303 is a continuation of application No. 16/310,328, granted, now 11,111,223, previously published as PCT/CN2017/088314, filed on Jun. 14, 2017.
Claims priority of application No. 201610416179.8 (CN), filed on Jun. 14, 2016; and application No. 201610493910.7 (CN), filed on Jun. 29, 2016.
Prior Publication US 2020/0157065 A1, May 21, 2020
Int. Cl. C07D 271/06 (2006.01)

CPC C07D 271/06 (2013.01) [C07B 2200/13 (2013.01)]

7 Claims

1. A crystalline Form CS1 of ozanimod hydrochloride, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 26.1°±0.20°, 24.4°±0.20° and 20.1°±0.20° using CuKα radiation.